BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Biotech catalysts in 2025-11

180 industry Phase 2/3 trial readout(s) and 37 FDA decision event(s). Readouts include completed (ACTUAL) and still-estimated primary completion dates in this month, any status.

← 2025-10 | 2025-12 →

FDA decision events

DateEventStatusCompanyDrugSource
2025-11-03FDA approvalapprovedUCB INCKYGEVVIApproved 2025-11-03: KYGEVVI (NDA219792 ORIG1)
2025-11-04Complete response lettercomplete responseBiohaven Therapeutics, Ltd. BHVN(troriluzole) capsulesCRL 2025-11-04: Biohaven Therapeutics, Ltd. NDA 210862 ((troriluzole) capsules)
2025-11-04FDA approvalapprovedABBVIE ABBVLINZESSApproved 2025-11-04: LINZESS (NDA202811 SUPPL22)
2025-11-05FDA approvalapprovedINTRA-CELLULARCAPLYTAApproved 2025-11-05: CAPLYTA (NDA209500 SUPPL16)
2025-11-06FDA AdComheldAdCom 2025-11-06: Digital Health Advisory Committee
2025-11-06Complete response lettercomplete responseAccord Healthcare Inc.bendamustine hydrochloride injectionCRL 2025-11-06: Accord Healthcare Inc. NDA 216987 (bendamustine hydrochloride injection)
2025-11-06FDA approvalapprovedJANSSEN BIOTECHDARZALEX FASPROApproved 2025-11-06: DARZALEX FASPRO (BLA761145 SUPPL29)
2025-11-13FDA AdComheldAdCom 2025-11-13: Pediatric Advisory Committee (PAC)
2025-11-13FDA approvalapprovedSHANGHAI HENLIUS BIOTECHPOHERDYApproved 2025-11-13: POHERDY (BLA761450 ORIG1)
2025-11-13FDA approvalapprovedKURA KURAKOMZIFTIApproved 2025-11-13: KOMZIFTI (NDA220305 ORIG1)
2025-11-18FDA approvalapprovedGENMAB US, INC. GMABEPKINLYApproved 2025-11-18: EPKINLY (BLA761324 SUPPL9)
2025-11-18FDA approvalapprovedARROWHEAD ARWRREDEMPLOApproved 2025-11-18: REDEMPLO (NDA219947 ORIG1)
2025-11-19FDA approvalapprovedTEVA TEVAIGALMIApproved 2025-11-19: IGALMI (NDA215390 SUPPL2)
2025-11-19FDA approvalapprovedASTRAZENECA AZNKOSELUGOApproved 2025-11-19: KOSELUGO (NDA213756 SUPPL6)
2025-11-19FDA approvalapprovedBAYER HEALTHCAREHYRNUOApproved 2025-11-19: HYRNUO (NDA219972 ORIG1)
2025-11-19FDA approvalapprovedAMGEN INC AMGNIMDELLTRAApproved 2025-11-19: IMDELLTRA (BLA761344 SUPPL1)
2025-11-19FDA approvalapprovedREGENERON PHARMACEUTICALS REGNEYLEA HDApproved 2025-11-19: EYLEA HD (BLA761355 SUPPL10)
2025-11-19FDA approvalapprovedJANSSEN BIOTECHDARZALEX FASPROApproved 2025-11-19: DARZALEX FASPRO (BLA761145 SUPPL32)
2025-11-20FDA approvalapprovedELI LILLY AND CO LLYRETEVMOApproved 2025-11-20: RETEVMO (NDA218160 SUPPL6)
2025-11-20FDA approvalapprovedELI LILLY AND CO LLYRETEVMOApproved 2025-11-20: RETEVMO (NDA213246 SUPPL15)
2025-11-21FDA approvalapprovedESPERION THERAPS INCNEXLETOLApproved 2025-11-21: NEXLETOL (NDA211616 SUPPL24)
2025-11-21FDA approvalapprovedESPERION THERAPS INCNEXLIZETApproved 2025-11-21: NEXLIZET (NDA211617 SUPPL29)
2025-11-21FDA approvalapprovedCHECKPOINT THERAPEUTICS INCUNLOXCYTApproved 2025-11-21: UNLOXCYT (BLA761297 SUPPL1)
2025-11-21FDA approvalapprovedMERCK SHARP DOHME MRKKEYTRUDAApproved 2025-11-21: KEYTRUDA (BLA125514 SUPPL188)
2025-11-21FDA approvalapprovedTAKEDA PHARMS USA TAKLIVTENCITYApproved 2025-11-21: LIVTENCITY (NDA215596 SUPPL7)
2025-11-21FDA approvalapprovedMERCK SHARP DOHME MRKKEYTRUDA QLEXApproved 2025-11-21: KEYTRUDA QLEX (BLA761467 SUPPL1)
2025-11-21FDA approvalapprovedNOVO NVOWEGOVY WEGOVY FLEXTOUCH WEGOVY HDApproved 2025-11-21: WEGOVY; WEGOVY FLEXTOUCH; WEGOVY HD (NDA215256 SUPPL23)
2025-11-21FDA approvalapprovedASTELLASPADCEVApproved 2025-11-21: PADCEV (BLA761137 SUPPL32)
2025-11-24Complete response lettercomplete responseAlvotech USA Inc. ALVOAVT06CRL 2025-11-24: Alvotech USA Inc. BLA 761435 (AVT06)
2025-11-24FDA approvalapprovedGENENTECH INCTECENTRIQ HYBREZAApproved 2025-11-24: TECENTRIQ HYBREZA (BLA761347 SUPPL4)
2025-11-24FDA approvalapprovedBRISTOL-MYERS SQUIBB BMYOPDIVO QVANTIGApproved 2025-11-24: OPDIVO QVANTIG (BLA761381 SUPPL5)
2025-11-25FDA approvalapprovedNOVARTIS NVSSCEMBLIXApproved 2025-11-25: SCEMBLIX (NDA215358 SUPPL12)
2025-11-25FDA approvalapprovedOTSUKA PHARM CO LTDVOYXACTApproved 2025-11-25: VOYXACT (BLA761434 ORIG1)
2025-11-25FDA approvalapprovedASTRAZENECA UK LTD AZNIMFINZIApproved 2025-11-25: IMFINZI (BLA761069 SUPPL52)
2025-11-26Complete response lettercomplete responseAlvotech USA Inc. ALVOAVTO5CRL 2025-11-26: Alvotech USA Inc. BLA 761461 (AVTO5)
2025-11-28FDA approvalapprovedSAMSUNG BIOEPIS CO LTDEPYSQLIApproved 2025-11-28: EPYSQLI (BLA761340 ORIG2)
2025-11-28FDA approvalapprovedLUPIN LTDARMLUPEGApproved 2025-11-28: ARMLUPEG (BLA761212 ORIG1)

Trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2025-11 est.P3Winston LaboratoriesNCT01341548 Civamide Nasal Solution for Cluster HeadacheEpisodic Cluster Headacheunknown180
2025-11 est.P3Korea Otsuka Pharmaceutical Co., Ltd.NCT03423680 A Study of Abilify® Tablet(Aripiprazole) as an Adjunctive Treatment in the Bipolar DepressionDepression, Bipolarunknown390
2025-11 est.P2Heron Therapeutics HRTXNCT03922048 Pediatric Postoperative Analgesia Herniorrhaphy StudyAnalgesiawithdrawn
2025-11 est.P1/P2Treadwell Therapeutics, IncNCT04521413 Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid MalignanciesAdvanced Solid Malignanciesunknown170
2025-11 est.P1/P2Deciphera Pharmaceuticals, LLCNCT05080621 Ripretinib in Combination With Binimetinib in Patients With Gastrointestinal Stromal Tumor (GIST)Gastrointestinal Stromal Tumorswithdrawn
2025-11 est.P1/P2Perceive Biotherapeutics, Inc.NCT05380492 Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular DegenerationAge-related Macular Degeneration; Geographic Atrophyunknown45
2025-11 est.P2/P3Shanghai JMT-Bio Inc.NCT05427383 KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line TherapyStomach Cancerrecruiting286
2025-11 est.P1/P2Intima Bioscience, Inc.NCT05566223 CISH Inactivated TILs in the Treatment of NSCLCCarcinoma, Non-Small-Cell Lung; Metastatic Non Small Cell Lung Cancer; Stage IV Non-small Cell Lung withdrawn
2025-11 est.P1/P2Beijing Mabworks Biotech Co., Ltd.NCT05806099 A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy Study of MBS303 in B-Cell NHLNon-Hodgkin's Lymphomarecruiting132
2025-11 est.P1/P2BiocadNCT06120582 Study of the Safety, Pharmacodynamics and Efficacy of ANB-002 in Patients With Hemophilia B (SAFRAN)Hemophilia Brecruiting28
2025-11 est.P2Beacon Therapeutics BBTNCT06275620 A Study Comparing Two Doses of AGTC-501 in Male Participants With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (DAWN)X-Linked Retinitis Pigmentosaenrolling by invitation24
2025-11 est.P1/P2Lantheus Medical Imaging LNTHNCT06298916 64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract CancerMetastatic Sarcoma; Esophageal Cancer; Gastric Cancer; Pancreatic Cancer; Colorectal Cancer; Sarcomarecruiting26
2025-11 est.P1/P2ENCellNCT06328725 Evaluate the Efficacy and Safety of EN001 in Patients With Duchenne Muscular DystrophyDuchenne Muscular Dystrophyunknown88
2025-11 est.P3Changchun GeneScience Pharmaceutical Co., Ltd.NCT06449027 Safety, Efficacy and Pharmacokinetic Behavior of Leuprolide Injectable Emulsion for Premenopausal Breast Cancer Subjects.Breast Cancer Subjectsactive not recruiting211
2025-11 est.P3TBF Genie TissulaireNCT06450470 Use of a Freeze-dried Amniotic Membrane Post Crosslinking in Subjects With Progressive KeratoconusProgressive Keratoconusrecruiting116
2025-11 est.P2Laboratorio Elea Phoenix S.A.NCT06629389 Clinical Trial with Cannabidiol (Kanbis®) for Parkinson Disease SymptomsParkinson Diseaserecruiting88
2025-11 est.P1/P2Helios Cardio Inc.NCT06730828 Amiodarone-Infused CardiaMend Patches for the Prevention of New-Onset POAF in Cardiac Surgery SubjectsAtrial Fibrillation, Postoperativerecruiting80
2025-11 est.P2Aer TherapeuticsNCT06731959 A Study to Investigate Using Inhaled Fexlamose to Treat Adult Participants Who Have Moderate to Severe COPDCOPDnot yet recruiting100
2025-11 est.P1/P2Rion Inc.NCT06793748 Study to Evaluate the Safety, Tolerability, and Efficacy of PEP-TISSEEL in Subjects With Chronic Radiation UlcerChronic Radiation Ulcernot yet recruiting184
2025-11 est.P2Guangdong Hengrui Pharmaceutical Co., LtdNCT06875934 A Trial Comparing SHR-1139 Injection With Placebo in Patients With Moderate-to-severe Plaque PsoriasisModerate to Severe Plaque Psoriasisactive not recruiting145
2025-11-01 est.P1/P2CERM INC.NCT06869252 Autologous Adipose Cells TherapyHair Loss/Baldness; Wrinkle Appearance; Volume; Fine Lines; Skin Elasticity; Hair Thinning; Skin Pigrecruiting40
2025-11-01 est.P2ORA, Inc.NCT07068958 A Study Evaluating the Efficacy and Safety of RCI001 Ophthalmic Solution Compared to Placebo in Subjects With Dry EyeDry Eye Disease (DED)not yet recruiting200
2025-11-02P3Adlai Nortye Biopharma Co., Ltd. ANLNCT04338399 The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCCHead and Neck Cancercompleted487
2025-11-02P3Immunovant Sciences GmbH IMVTNCT05517421 Study to Assess Batoclimab in Participants With Active Thyroid Eye DiseaseThyroid Eye Diseasecompleted114
2025-11-03P2Astellas Pharma Europe Ltd.NCT01294020 Study to Compare the Pharmacokinetics of Tacrolimus in Stable Pediatric Allograft Recipients Converted From Prograf® to Advagraf®Intestine Transplantation; Kidney Transplantation; Lung Transplantation; Liver Transplantation; Hearcompleted81
2025-11-03P2Eisai Co., Ltd.NCT04238715 A Study of E7090 in Participants With Unresectable Advanced or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor (FGFR) 2 Gene FusionCholangiocarcinomacompleted63
2025-11-03P1/P2Visara, Inc.NCT05456828 A Study of ASKG712 in Patients With Neovascular Age-Related Macular DegenerationNeovascular Age-related Macular Degenerationcompleted56
2025-11-03P3GlaxoSmithKlineNCT05630820 Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 2)Chronic Hepatitis B; Hepatitis B, Chroniccompleted857
2025-11-03P2Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.NCT06542614 Treatment of Moderate to Severe Plaque PsoriasisPlaque Psoriasiscompleted209
2025-11-03P3RDC Clinical Pty LtdNCT06837961 LC-Plasma on Immune Response and Reducing Symptoms of Upper Respiratory Infectious DiseasesHealthy Volunteer; Immune Responsecompleted241
2025-11-03P2IVIEW Therapeutics Inc.NCT07161011 Phase 2b Controlled Study of Dosing Techniques - Part BDry Eyecompleted15
2025-11-04P3AstraZeneca AZNNCT04008706 Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia PatientsChronic Lymphocytic Leukemiacompleted552
2025-11-04P3Novartis Pharmaceuticals NVSNCT04788615 Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMSMultiple Sclerosiscompleted185
2025-11-04P3ModernaTX, Inc.NCT05085366 A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of AgeCytomegalovirus Infectionterminated7454
2025-11-04P2Glycomine, Inc.NCT05549219 24-Week Study to Assess the PD, Safety, Tolerability, and PK of GLM101 in Participants With PMM2-CDGPmm2-CDG; Phosphomannomutase 2 Deficiencycompleted27
2025-11-04P3A. Vogel AGNCT06795776 Eschscholzia StudySleepcompleted104
2025-11-04P3Colgate Palmolive CLNCT07257042 Oothpaste Containing 8% Arginine Compared to Colgate Cavity Protection Toothpaste in Reducing Dentinal HypersensitivityHypersensitivitycompleted80
2025-11-05P2Merck Sharp & Dohme LLC MRKNCT02625961 Study of Pembrolizumab (MK-3475) and Pembrolizumab With Other Investigational Agents in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-Bladder Cancerterminated296
2025-11-05P3Neurocrine Biosciences NBIXNCT04400331 Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington DiseaseChorea, Huntingtonterminated154
2025-11-05P1/P2Genmab GMABNCT05721222 Trial of PRO1160 (GEN1160) in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) (PRO1160-001)Renal Cell Carcinoma; Nasopharyngeal Carcinoma; Non Hodgkin Lymphomaterminated42
2025-11-05P2Noah Pharmaceuticals, Inc. NOAHNCT06597058 Phase 2 Estimation Study of Fixed Dose Drugs Combination Type of PolypillAlzheimer Diseasecompleted121
2025-11-05P3Haisco Pharmaceutical Group Co., Ltd.NCT06799546 A Phase III Study to Evaluate the Efficacy and Safety of HSK39297 in Patients With Paroxysmal Nocturnal Hemoglobinuria Who Are Naive to Complement Inhibitor ThePNHcompleted73
2025-11-06P2Otsuka Pharmaceutical Development & Commercialization, Inc.NCT05593029 A Trial of the Safety and Efficacy of SEP-363856 in the Treatment of Adults With Major Depressive DisorderMajor Depressive Disordercompleted929
2025-11-06P2/P3Abcuro, Inc.NCT05721573 A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body MyositisInclusion Body Myositiscompleted272
2025-11-06P3DBV Technologies DBVTNCT05741476 Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Children 4-7 Years of AgeAllergy, Peanutactive not recruiting600
2025-11-06P2Regor Pharmaceuticals Inc.NCT06867718 Study of Once-Daily Oral RGT001-075 Compared With Placebo in Adults With Obesity or Are Overweight With Weight-Related Health ConditionsObesity or Overweightcompleted267
2025-11-07P1/P2Ocellaris Pharma, Inc.NCT04260802 A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic CancersCancer; Neoplasms; Metastatic Cancer; Triple Negative Breast Cancer; Gastric Cancer; Cervical Cancerterminated73
2025-11-07P3Scynexis, Inc. SCYXNCT05178862 A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral FlucCandidiasis, Invasive; Candidemiaterminated68
2025-11-07P3Pfizer PFENCT05348915 A Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants With Sickle Cell DiseaseSickle Cell Disease; Vaso-occlusive Crisis; Vaso-occlusive Pain Episode in Sickle Cell Diseaseterminated242
2025-11-07P2Fujian Shengdi Pharmaceutical Co., Ltd.NCT06194201 A Trial of Intravenous HRS9432 in the Treatment of Subjects With Candidemia and/or Invasive CandidiasisPatients With Candidemia and/or Invasive Candidiasiscompleted61
2025-11-07P2Biohaven Therapeutics Ltd. BHVNNCT06419608 Efficacy and Safety Study of BHV-7000 Monotherapy in Major DepressionMajor Depressive Disordercompleted336
2025-11-07 est.P2Reinhold ViethNCT07109609 Topical Menthol For Tear SecretionHealthy; Dry Eyesenrolling by invitation30
2025-11-09 est.P1/P2Shanghai Jiatan Pharmatech Co., LtdNCT06117566 A Study of WX390 Combined With Toripalimab in Patients With Advanced Solid TumorsSolid Tumorrecruiting100
2025-11-09P1/P2Unither Pharmaceuticals, FranceNCT07075224 Pharmacodynamics of a Fixed Dose Combination of 0.34% Tropicamide and 2.5% Phenylephrine Hydrochloride, Eye Drop, SolutionMydriasiscompleted20
2025-11-10P2Leidos Life Sciences LDOSNCT05077332 LEAP-CT for Treatment of COVID-19 Patients (Master Protocol)2019 Novel Coronavirus Disease; 2019 Novel Coronavirus Infection; 2019-nCoV Disease; 2019-nCoV Infeccompleted4
2025-11-10P3AbbVie ABBVNCT06399718 A Study to Assess BOTOX Injections for the Change of Masseter Muscle Prominence in Adult ParticipantsMasseter Muscle Prominencecompleted207
2025-11-10P3Mannkind Corporation MNKDNCT06418711 ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation SuspensionMAC Lung Disease; Treatment Refractory MAC Lung Disease; Mycobacterium Infections, Nontuberculousterminated132
2025-11-10 est.P1/P2Sinocelltech Ltd.NCT06801509 A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Recombinant Herpes Zoster VaccineHerpes Zosternot yet recruiting540
2025-11-10P2Eli Lilly and Company LLYNCT06859294 A Study of LY3541860 in Adult Participants With Moderately to Severely Active Rheumatoid ArthritisRheumatoid Arthritisterminated35
2025-11-10P3Shenzhen Salubris Pharmaceuticals Co., Ltd.NCT07704697 Assess Sacubitril/Allisartan and Amlodipine in Patients With Essential Hypertension Uncontrolled With Sacubitril/AllisartanEssential Hypertensioncompleted346
2025-11-11P3GlaxoSmithKlineNCT05630807 Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 1)Chronic Hepatitis B; Hepatitis B, Chroniccompleted981
2025-11-11P2Cyrano Therapeutics, Inc.NCT06019000 Study of CYR-064 Versus Placebo in Patients.Hyposmiacompleted151
2025-11-11P3Boryung Pharmaceutical Co., LtdNCT06165250 A Study to Evaluate the Efficacy and Safety of Co-administrated BR1018B and BR1018CEssential Hypertension; Primary Hypercholesterolemiacompleted151
2025-11-11P2Alkermes, Inc. ALKSNCT06555783 A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 2Narcolepsy Type 2completed93
2025-11-12P3Eli Lilly and Company LLYNCT04396236 A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With MigraineMigraineterminated847
2025-11-12P2Bristol-Myers Squibb BMYNCT05136677 A Study to Evaluate Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin for Unresectable Pleural Mesothelioma in Chinese PaMesothelioma, Malignantcompleted102
2025-11-12P2Neurocrine Biosciences NBIXNCT05226780 Extension Study to Evaluate How Safe and Tolerable NBI-921352 is as an Adjunctive Therapy for Participants With SCN8A-DEESCN8A Developmental and Epileptic Encephalopathy Syndrometerminated8
2025-11-12P2Curacle Co., Ltd.NCT05718375 Phase IIb Clinical Trial for the Efficacy and Safety by CU01-1001 for 24 Weeks in Type 2 DM Patients With AlbuminuriaDiabetic Nephropathiescompleted240
2025-11-12P2/P3Praxis Precision Medicines PRAXNCT05818553 A Clinical Trial of PRAX-562 in Subjects With Developmental and Epileptic Encephalopathies (DEE)SCN2A Encephalopathy; SCN8A Encephalopathyactive not recruiting77
2025-11-12 est.P1/P2GI Innovation, Inc.NCT05824975 A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or TraAdvanced Solid Tumor; Metastatic Solid Tumor; Soft Tissue Sarcoma (STS); Platinum-resistant Ovarian recruiting358
2025-11-12P3Ascletis Pharmaceuticals Co., Ltd.NCT06248008 A Study to Evaluate Safety of ASC40 Tablets in Patients With Moderate to Severe Acne VulgarisAcnecompleted240
2025-11-12P2AbbVie ABBVNCT06605599 Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II DisorderBipolar I Disorder; Bipolar II Disordercompleted161
2025-11-13P2/P3Vertex Pharmaceuticals Incorporated VERXNCT03655678 A Safety and Efficacy Study Evaluating CTX001 in Participants With Transfusion-Dependent β-ThalassemiaBeta-Thalassemia; Thalassemia; Genetic Diseases, Inborn; Hematologic Diseases; Hemoglobinopathiescompleted59
2025-11-13 est.P1/P2Inventage Lab., Inc.NCT05345509 A Clinical Trial to Access Pharmacokinetic Profiles and Safety of IVL3003.Alzheimer Diseaseactive not recruiting62
2025-11-13P2ModernaTX, Inc.NCT05606965 A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy AdultsInfluenzacompleted172
2025-11-13P3Zenas BioPharma (USA), LLC ZBIONCT05662241 A Phase 3 Study of Obexelimab in Patients With IgG4-Related DiseaseIgG4 Related Diseaseactive not recruiting194
2025-11-13P3COMPASS Pathways CMPSNCT05711940 Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRDTreatment Resistant Depressionactive not recruiting572
2025-11-13P1/P2Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT05745363 Clinical Study of AL2846 Capsule in the Treatment of Differentiated Thyroid CancerDifferentiated Thyroid Cancercompleted33
2025-11-13P2Shanghai Hengrui Pharmaceutical Co., Ltd.NCT06236295 Investigating the Safety and Efficacy of SHR6508 Injection in the Treatment of Secondary Hyperparathyroidism in Hemodialysis Patients : A Multicenter, Long-termSecondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease (CKD) on Hemodialysiscompleted303
2025-11-13P3Shandong Suncadia Medicine Co., Ltd.NCT06672172 A Study of HRS-7535 Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequately Controlled With Diet and ExerciseType 2 Diabetescompleted284
2025-11-14P3Eli Lilly and Company LLYNCT03432286 A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic MigraineEpisodic Migraineactive not recruiting533
2025-11-14P3Sanofi SNYNCT04458051 Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS)Primary Progressive Multiple Sclerosiscompleted767
2025-11-14P2CinDome Pharma, Inc.NCT05832151 A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic GastroparesisDiabetic Gastroparesiscompleted382
2025-11-14P3Eli Lilly and Company LLYNCT05931367 A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the KneeObesity; Overweight; Osteo Arthritis Kneecompleted445
2025-11-14P1/P2Auregen Biotherapeutics, SANCT06072040 Subcutaneous Implant Combination Product (AUR-201) in Patients With Unilateral MicrotiaMicrotiaterminated3
2025-11-14P1/P2Auregen Biotherapeutics, SANCT06078566 Long-Term Follow-Up Study of Unilateral Microtia Patients Implanted With AUR-201Microtiaterminated1
2025-11-14P1/P2Clarametyx Biosciences, Inc.NCT06159725 A Study To Evaluate The Safety Of CMTX-101 In People With Cystic FibrosisPersistent Infection; Cystic Fibrosiscompleted43
2025-11-14P3Sanofi Pasteur, a Sanofi Company SNYNCT06284915 Study on Immunogenicity and Safety of a Meningococcal ACYW Conjugate Vaccine in Healthy Infants and ToddlersMeningococcal Immunisation; Healthy Volunteerscompleted840
2025-11-14P2Ascendis Pharma Growth Disorders A/S ASNDNCT06433557 A Phase 2 Clinical Trial to Evaluate Efficacy, Safety, and Tolerability of Navepegritide in Combination With Lonapegsomatropin in Children With AchondroplasiaAchondroplasiaactive not recruiting22
2025-11-14P2Alcon Research ALCNCT06441643 Next Generation RocklatanOpen Angle Glaucoma; Ocular Hypertensioncompleted646
2025-11-14P2Enterprise Therapeutics Ltd EPDNCT06478706 A Two-Part Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Repeat Doses of Inhaled ETD001 in People With Cystic FibrosisCystic Fibrosiscompleted57
2025-11-15P1/P2Lokon Pharma ABNCT02705196 LOAd703 Oncolytic Virus Therapy for Pancreatic CancerPancreatic Cancercompleted51
2025-11-15P3Sanofi Pasteur, a Sanofi Company SNYNCT05794230 Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in IndMeningococcal Immunisation; Healthy Volunteerscompleted1528
2025-11-16P2medac GmbHNCT03156790 PK, PD, Safety and Immunogenicity of Spectrila in Adults With Acute B-cell Lymphoblastic LeukaemiaAcute B-Cell Lymphoblastic Leukaemiaterminated40
2025-11-16 est.P3CelgeneNCT06232707 A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)Multiple Myelomawithdrawn
2025-11-16 est.P2/P3Novavax NVAXNCT06482359 Lot Consistency Study of COVID-19 and Influenza Combination VaccineCOVID-19; Influenzawithdrawn
2025-11-17 est.P3Novartis Pharmaceuticals NVSNCT03081234 Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- Intermediate Risk Early Breast CancerBreast Cancerwithdrawn
2025-11-17P2Veralox TherapeuticsNCT05785819 A Phase 2 Study of VLX-1005 Versus Placebo in Suspected Heparin Induced ThrombocytopeniaThrombocytopenia, Immune; Heparin Induced Thrombocytopeniaterminated24
2025-11-17P2Trishula Therapeutics, Inc.NCT06119217 Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC PatientsPancreatic Cancercompleted194
2025-11-17P2Sarfez Pharmaceuticals, Inc.NCT06206512 Effect of Extended Release Torsemide in Patients With Congestive Heart Failure and Overactive BladderHeart Failure; Overactive Bladder; Incontinencecompleted24
2025-11-17P3ModernaTX, Inc.NCT06694389 Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 Vaccine (SARS-CoV-2 [COVID-19] and Influenza) in Adults ≥50 Years of AgeCOVID-19; Influenzacompleted2457
2025-11-17P2Evommune, Inc. EVMNNCT06723405 Efficacy Study of EVO301 in Moderate to Severe Atopic DermatitisAtopic Dermatitis (AD); Eczema; Eczema Atopic Dermatitiscompleted71
2025-11-17P3Janssen Research & Development, LLCNCT06934226 A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque PsoriasisPlaque Psoriasisactive not recruiting752
2025-11-18P3F2G LtdNCT05101187 Olorofim Aspergillus Infection StudyInvasive Aspergillosiscompleted225
2025-11-18P3Vifor Fresenius Medical Care Renal PharmaNCT05136664 Trial Evaluating the Efficacy and Safety of Patiromer in Chinese SubjectsHyperkalemia; Renal Insufficiency, Chroniccompleted262
2025-11-18P2AudioCure Pharma GmbHNCT05776459 Efficacy and Safety of AC102 Compared to Steroids in Adults With Idiopathic Sudden Sensorineural Hearing Loss (ISSNHL)Hearing Loss, Sensorineuralcompleted223
2025-11-18P2NovoCure Ltd. NVCRNCT06390059 EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic DuMetastatic Pancreatic Ductal Adenocarcinomacompleted84
2025-11-18P3Eli Lilly and Company LLYNCT06588296 Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or OverweightPsoriatic Arthritis; Obesitycompleted279
2025-11-18P2Organ, Tissue, Regeneration, Repair and ReplacementNCT06700824 A Trial to Assess the Efficacy and Safety of OTR4132-MD in Patients With Acute Ischemic StrokeEndovascular Thrombectomy; Ischemic Cerebrovascular Accidentcompleted60
2025-11-18P2Shandong Suncadia Medicine Co., Ltd.NCT06816251 A Phase II Clinical Study of HRS-1893 in Non-obstructive Hypertrophic CardiomyopathyNon-obstructive Hypertrophic Cardiomyopathycompleted84
2025-11-18P2TriGemX Bio, Inc.NCT07116499 A Study of K-645 in the Treatment of Multiple Migraine AttacksMigraineterminated134
2025-11-19P3Amgen AMGNNCT03836040 Efficacy and Safety of Erenumab in Pediatric Participants With Episodic MigraineMigraineactive not recruiting457
2025-11-19P2AbbVie ABBVNCT05291234 A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-9Alzheimer's Disease (AD)completed106
2025-11-19P3CSL BehringNCT05819775 CSL312_3003 Safety and Pharmacokinetic Study in Subjects 2 to 11 Years of Age With Hereditary AngioedemaHereditary Angioedema (HAE)completed22
2025-11-19P3Novo Nordisk A/S NVONCT06065540 A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes TType 2 Diabetes Mellituscompleted2734
2025-11-20P1/P2AkesoNCT05214482 A Study of AK112 in Advanced Malignant TumorsAdvanced Malignant Tumorscompleted154
2025-11-20P3Hoffmann-La RocheNCT05271409 A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Myelin Oligodendrocyte Glycoprotein AntiboMyelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)active not recruiting139
2025-11-20P3Amgen AMGNNCT05565560 A Study to Assess the Efficacy and Safety of Apremilast in Japanese Pediatric Participants With Moderate to Severe Plaque PsoriasisPlaque Psoriasiscompleted21
2025-11-20P2Melinta Therapeutics, LLCNCT05599295 Study to Evaluate the Safety of Intravenous Oritavancin for the Treatment of Children With Skin InfectionsAcute Bacterial Skin and Skin Structure Infectioncompleted118
2025-11-20P1/P2InxMed (Shanghai) Co., Ltd.NCT06030258 IN10018 Combination Therapy in Treatment-naïve ES-SCLCSmall Cell Lung Cancer Extensive Stageactive not recruiting120
2025-11-20P3AbbVie ABBVNCT06068855 A Study to Assess the Effectiveness of BOTOX (Botulinum Toxin Type A) Injections for the Change of Masseter Muscle Prominence in Adult ParticipantsMasseter Muscle Prominencecompleted249
2025-11-20P2Hangzhou Yirui Pharmaceutical Technology Co., LtdNCT06309355 Topical YR001 Ointment in Adult With Mild to Moderate Atopic DermatitisAtopic Dermatitiscompleted35
2025-11-20P1/P2Genmab GMABNCT06391775 Trial to Assess the Safety and Preliminary Efficacy of GEN1055 on Malignant Solid Tumors as Monotherapy and as Combination TherapyMalignant Solid Tumorterminated21
2025-11-20P2JemincareNCT06438757 Trial of JYB1904 in Patients With Allergic AsthmaAllergic Asthmacompleted69
2025-11-20P3Cutia Therapeutics(Wuxi)Co.,LtdNCT06585696 A Phase 3 Clinical Study to Evaluate the Efficacy and Safety of Botulinum Toxin Type A for Injection (CU-20101)Glabellar Frown Linescompleted554
2025-11-20P2Merck Sharp & Dohme LLC MRKNCT06664801 A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) (MK-7962-024)Pulmonary Arterial Hypertensioncompleted164
2025-11-20P1/P2Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT06851442 Clinical Trial of Evaluating TQB3912 Tablets Combined With Fulvestrant Injection±TQB3616 Capsules for Locally Advanced or Metastatic Hormone Receptor(HR)-PositiBreast Cancerterminated8
2025-11-20 est.P2Beijing Tide Pharmaceutical Co., LtdNCT07121101 To Evaluate the Safety, Efficacy and Kinetic Characteristics of TRD205 Tablets for Postoperative Analgesia After Unilateral Hip ArthroplastyPostoperative Analgesia After Unilateral Hip Arthroplastynot yet recruiting40
2025-11-21P3Insmed Incorporated INSMNCT04677569 Study to Evaluate ALIS (Amikacin Liposome Inhalation Suspension) in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Mycobacterium Infections, Nontuberculouscompleted425
2025-11-21P3CSL BehringNCT04739059 Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema AttacksHereditary Angioedemacompleted171
2025-11-21P1/P2Blueprint Medicines CorporationNCT04773782 A Study of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA SignalingSolid Tumor, Unspecified, Child; Relapsed Solid Neoplasm; CNS Tumorcompleted29
2025-11-21P1/P2Amgen AMGNNCT05322577 A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal JuncGastric Cancer; Gastroesophageal Junction Cancerterminated72
2025-11-21P2Novo Nordisk A/S NVONCT06409130 Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver DiseaseAlcohol-related Liver Diseasecompleted270
2025-11-21P2AstraZeneca AZNNCT06579092 Effects of AZD5004 in Adults Who Are Living With Obesity or Overweight With at Least 1 Weight-related ComorbidityObesity or Overweightcompleted310
2025-11-21P3Eli Lilly and Company LLYNCT06584916 A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAObesity; Overweightcompleted376
2025-11-21P2Palvella Therapeutics, Inc. PVLANCT06653842 A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Cutaneous Venous MalformatioCutaneous Venous Malformationsactive not recruiting15
2025-11-21P2Korea Arlico Pharm. Co., LtdNCT07061925 To Evaluate the Efficacy and Safety of ALC-2203 in Patients With Acute BronchitisAcute Bronchitiscompleted169
2025-11-21P2The United Bio-Technology (Hengqin) Co., Ltd.NCT07163624 UBT251 Injection Phase II (Type 2 Diabetes Mellitus) StudyType 2 Diabetes Mellitus (T2DM)completed211
2025-11-22P1/P2Guangdong Hengrui Pharmaceutical Co., LtdNCT06713499 A Phase Ib/II Study to Investigate the Safety of SHR-1819 in Children and Adolescents With Moderate-to-severe Atopic DermatitisChildren and Adolescents With Moderate-to-severe Atopic Dermatitiscompleted51
2025-11-22P2Portal Therapeutics, Inc.NCT06971900 GATEWAY: A Phase 2a Study of PORT-77 in Adults With Erythropoietic ProtoporphyriaErythropoietic Protoporphyria (EPP)completed28
2025-11-24P3AstraZeneca AZNNCT05110261 Evaluate the Safety and Efficacy of Nirsevimab in Healthy Preterm and Term Infants in ChinaLower Respiratory Tract Infectioncompleted800
2025-11-24P2Kite, A Gilead CompanyNCT05459571 Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell LymphomaRelapsed or Refractory Large B-cell Lymphomacompleted35
2025-11-24P3AstraZeneca AZNNCT06344104 A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants WiUncontrolled Hypertension; Resistant Hypertensioncompleted326
2025-11-24P3Colgate Palmolive CLNCT07276672 Efficacy of a Toothpaste Containing Hydrogen Peroxide as Compared to a Regular Fluoride Toothpaste Without Hydrogen Peroxide in the Immediate Removal of Tooth SWhiteningcompleted80
2025-11-25P2RHEACELL GmbH & Co. KGNCT04971161 Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of CVU (Phase IIb)Skin Ulcer Venous Stasis Chroniccompleted159
2025-11-25P2/P3Hutchmed HCMNCT05535933 HMPL-523 (Sovleplenib) in the Treatment of Warm Antibody Autoimmune Hemolytic AnemiaWarm Antibody Autoimmune Hemolytic Anemiaactive not recruiting111
2025-11-25P2Altimmune, Inc. ALTNCT05989711 IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH)Non-Alcoholic Steatohepatitis (NASH)completed212
2025-11-25P3Sanofi SNYNCT06181435 A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-Dermatitis Atopiccompleted589
2025-11-25P3Bristol-Myers Squibb BMYNCT06253221 A Study to Evaluate Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic CardiomyopathyCardiomyopathy, Hypertrophicactive not recruiting44
2025-11-25P2Boehringer IngelheimNCT06335303 A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)Idiopathic Pulmonary Fibrosiscompleted322
2025-11-25P3AbbVie ABBVNCT06387394 A Study to Assess BOTOX Injections in Adult Participants for the Change of Masseter Muscle ProminenceMasseter Muscle Prominencecompleted202
2025-11-25P3Alvotech Swiss AG ALVONCT06570772 Study to Investigate Comparative Efficacy, Safety and Immunogenicity Between AVT16 and EntyvioUlcerative Colitisterminated301
2025-11-25 est.P2Marzieh EbrahimiNCT06687681 Injection of Active Allogeneic Natural Killer Cells in Patients With GliomasGlioma Glioblastoma Multiforme; High Grade Glioma (III or IV)recruiting40
2025-11-25P3Vincentage Pharma Co., LtdNCT06939296 A Research Study of VCT220 in Adult Chinese Participants With ObesityObesity; Overweightcompleted840
2025-11-26P2CUTISS AGNCT03229564 Study With an Autologous Dermo-epidermal Skin Substitute for the Treatment of Burns in ChildrenBurnsactive not recruiting12
2025-11-26P1/P2RemeGen Co., Ltd.NCT05508334 A Study to Assess the Safety and Tolerability of RC88 for Patients With Advanced Solid TumoursAdvanced Solid Tumourscompleted41
2025-11-26P2Keymed Biosciences Co.LtdNCT06116565 A Study of CM310 in Subjects With Moderate-to-Severe Atopic DermatitisAtopic Dermatitiscompleted263
2025-11-26P2Nektar Therapeutics NKTRNCT06340360 A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA)Alopecia Areatacompleted94
2025-11-26P2Chengdu Zenitar Biomedical Technology Co., LtdNCT06457425 A Phase II Clinical Trial of Flonoltinib Maleate Tablet in Intermediate-High Risk MyelofibrosisMF,PMF,PPV-MF,PET-MFactive not recruiting75
2025-11-27P3GB002, Inc.NCT05934526 Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)Pulmonary Arterial Hypertensioncompleted390
2025-11-27P3Jiangsu HengRui Medicine Co., Ltd.NCT06091748 Gallium (68Ga) Edotreotide PET/CT for Imaging Patients With Gastrointestinal Pancreatic Neuroendocrine TumorsAdvanced Gastroenteropancreatic Neuroendocrine Tumorcompleted69
2025-11-28P2Aurealis OyNCT06111183 Evaluation of AUP12602-C as New Topical Treatment for DFUs (DIAMEND STUDY)Diabetic Foot Ulcercompleted64
2025-11-28P3Angitia BiopharmaceuticalsNCT06115512 A Phase 3 Study of AGA111 in Patients With Degenerative Disc Disease Undergoing Lumbar Interbody FusionDegenerative Disc Diseaseterminated412
2025-11-28P2Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USANCT07132983 A Phase II Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Single Inhaled Doses of Ensifentrine-glycopyrrolate Fixed Dose Combination, EnsChronic Obstructive Pulmonary Diseasecompleted33
2025-11-29 est.P3RemeGen Co., Ltd.NCT05727397 Efficacy and Safety of RC28-E Versus AfliberceptWet Age-related Macular Degenerationunknown432
2025-11-30 est.P3CinnagenNCT03391934 Comparing Efficacy and Safety of Cetuximab (CinnaGen) Versus Erbitux® (Merck) in Metastatic Colorectal CancerMetastatic Colorectal Cancerunknown234
2025-11-30P1/P2Klus Pharma Inc.NCT04152499 Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)Epithelial Ovarian Cancer; Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma; Urothelactive not recruiting1410
2025-11-30 est.P1/P2Binhui Biopharmaceutical Co., Ltd.NCT04616443 OH2 Injection in Combination With HX008 for Melanoma.Melanomarecruiting60
2025-11-30P2IO BiotechNCT05077709 IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBCLung Cancer Non Small Cell; Head and Neck Squamous Cell Carcinoma; Urothelial Carcinoma Bladdercompleted63
2025-11-30P1/P2RS Oncology LLCNCT05278975 Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including MesotheliomaMalignant Pleural Effusion; Malignant Pleural Mesothelioma; Mesothelioma; Mesotheliomas Pleural; Mescompleted50
2025-11-30 est.P1/P2Frontera TherapeuticsNCT05858983 Gene Therapy in Subjects With Biallelic RPE65 Mutation-associated Retinal DystrophyBiallelic RPE65 Mutation-associated Retinal Dystrophyrecruiting9
2025-11-30 est.P1/P2Biotheus Inc.NCT05918445 PM8002 in the Treatment of Patients With Advanced Solid TumorsMalignant Neoplasmrecruiting380
2025-11-30 est.P1/P2SUNHO(China)BioPharmaceutical CO., Ltd.NCT05991583 A Clinical Trial to Evaluate Effect of IBB0979 in Patients With Advanced Malignant TumorsAdvanced Malignant Tumorsrecruiting25
2025-11-30 est.P1/P2Ascentawits Pharmaceuticals, LtdNCT06239155 A Phase I/II Study of AST-3424 in Subjects With Advanced Solid TumorsAdvanced Solid Tumors; Hepatocellular Carcinomaactive not recruiting51
2025-11-30 est.P3Leadiant Biosciences, Inc.NCT06260748 A Study of Chenodeoxycholic Acid (CDCA) in Newly Diagnosed Participants With Cerebrotendinous Xanthomatosis (CTX)Cerebrotendinous Xanthomatoseswithdrawn
2025-11-30 est.P3CSPC Ouyi Pharmaceutical Co., Ltd.NCT06451666 Safety and Efficacy Study of Pilocarpine HCl Ophthalmic Solution in Participants With PresbyopiaPresbyopiaunknown330
2025-11-30 est.P2Evon Medics LLCNCT06671132 Development and Evaluation of Computerized Chemosensory-Based Orbitofrontal Networks Training for Treatment of Pain (CBOT-P)Chronic Pain; Low Back Painunknown220
2025-11-30 est.P1/P2Jiangsu HengRui Medicine Co., Ltd.NCT06689163 A Study for the Treatment of Metastatic Prostate Cancer With HRS-1167 Tablets Combined With Abiraterone Acetate Tablets and PrednisoneProstate Cancerrecruiting66
2025-11-30P1/P2NGGT (Suzhou) Biotechnology Co., Ltd.NCT06706427 Safety and Efficacy Study of NGGT001 in Bietti Crystalline Corneoretinal Dystrophy SubjectsBietti Crystalline Corneoretinal Dystrophyactive not recruiting12
2025-11-30 est.P3Sinovac Biotech Co., Ltd SVANCT06734832 Efficacy, Safety, and Immunogenicity of the Bivalent Inactivated Enterovirus Vaccine (Vero Cell)Hand, Foot, and Mouth Disease(HFMD)recruiting8000

← 2025-10 | 2025-12 →

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.